Our findings support that CTP is the currently optimal neoadjuvant immunotherapy regimen for HER2-positive breast cancer, due to the best chance of achieving pCR and relatively modest toxicity profile compared with other treatments. The gene discussed is ERBB2; the disease is breast cancer.